Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Olfactory ensheathing cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Infarction, Middle Cerebral Artery
1 trial -
Omeprazole 40 MG
LEXICON PHARMACEUTICALS, INC.
Drug-drug Interaction
1 trial -
Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function
Biocodex
Patients with renal impairement
1 trial -
Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease
1 trial -
Oxycodone (OxyNorm®) Injection
Mundipharma Pty Limited
Pain
1 trial -
Oxycodone (OxyNorm®) Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pain
1 trial -
P3C541b Lipopeptide
United Therapeutics Europe Ltd
HIV Infections
1 trial -
PEGylated recombinant human interferon alpha-2b injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis B, Chronic
1 trial -
PENNVAX-B
INOVIO PHARMACEUTICALS, INC.
HIV-1 Infection
1 trial -
PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION
Zealand Pharma A/S
Healthy / hepatic impaired volunteers only study to assess PK parameters
1 trial -
PIC1 Injection
Chongqing Precision Biotech Co., Ltd
Non-Hodgkin Lymphoma
1 trial -
PMV via Puffhaler® device
Serum Life Science Europe GmbH
Prophylaxis for the Measles Infection
1 trial -
PRO 2000/5 Gel (P)
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial -
Palbociclib + Taselisib / Pictilisib
United Therapeutics Europe Ltd
Advanced Solid Tumours
1 trial -
Paracetamol 1000mg Tablets, Diphenhydramin-Hevert Injektionslösung, Diphenhydramine Hydrochloride Tablets 25 mg, LYNOZYFIC 200 mg concentrate for solution for infusion, LYNOZYFIC 5 mg concentrate for solution for infusion, Dexamethasone 3.3 mg/ml solution for injection/infusion, REGN17372
Lacuna Pharma Pty Ltd
Relapsed/Refractory Multiple Myeloma
1 trial -
Part 1
Harmony Biosciences Holdings
Drug Interaction
1 trial -
Pegylated Recombinant Candida Utilis Uricase for Injection
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Gout
1 trial -
Peldesine
Biocryst
HIV Infections
1 trial -
Pevifoscorvir Sodium (ALG-000184)
Aligos Therapeutics
Chronic Hepatitis B Infection
1 trial -
Pevifoscorvir Sodium (ALG-000184)
Aligos Therapeutics
Chronic Hepaititis B Infections
1 trial -
Pharmacokinetic study of colistimethate sodium
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options
1 trial -
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
Lacuna Pharma Pty Ltd
Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis
1 trial -
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors
Lacuna Pharma Pty Ltd
Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).
1 trial -
Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics
GlaxoSmithKline
Urinary Tract Infections
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources